T Siegal

Summary

Affiliation: Hadassah University Hospital
Country: Israel

Publications

  1. pmc Which drug or drug delivery system can change clinical practice for brain tumor therapy?
    Tali Siegal
    Gaffin Center for Neuro Oncology, Hadassah Hebrew University Medical Center, Ein Kerem, P O Box 12000, Jerusalem 91120, Israel
    Neuro Oncol 15:656-69. 2013
  2. doi request reprint CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?
    Tali Siegal
    Gaffin Center for Neuro Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Blood Rev 26:97-106. 2012
  3. ncbi request reprint Toxicity of treatment for neoplastic meningitis
    Tali Siegal
    Neuro Oncology Center, Hadassah Hebrew University Hospital, Ein Kerem, PO Box 12000, Jerusalem 91120, Israel
    Curr Oncol Rep 5:41-9. 2003
  4. ncbi request reprint Strategies for increasing drug delivery to the brain: focus on brain lymphoma
    Tali Siegal
    Neuro Oncology Center, Hadassah Hebrew University Hospital, Jerusalem, Israel
    Clin Pharmacokinet 41:171-86. 2002
  5. ncbi request reprint In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans
    T Siegal
    Department of Nuclear Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel
    J Neurosurg 92:599-605. 2000
  6. ncbi request reprint Cellular and secretory mechanisms related to delayed radiation-induced microvessel dysfunction in the spinal cord of rats
    T Siegal
    Department of Neurology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    Int J Radiat Oncol Biol Phys 36:649-59. 1996
  7. ncbi request reprint Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma
    E Zylber-Katz
    Division of Medicine, the Neuro Oncology Center, Hadassah University Hospital, Jerusalem, Israel
    Clin Pharmacol Ther 67:631-41. 2000
  8. doi request reprint Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience
    S Frenkel
    Department of Ophthalmology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Br J Ophthalmol 92:383-8. 2008
  9. doi request reprint Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption
    J Vicuna-Kojchen
    Department of Ophthalmology, Hadassah Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel
    Br J Ophthalmol 92:231-5. 2008
  10. pmc Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades
    Iris Lavon
    Gaffin Center for Neuro Oncology and the Department of Neurology, Hadassah Hebrew University Medical Center, Ein Kerem, PO Box 12000, Jerusalem 91120, Israel
    Neuro Oncol 12:173-80. 2010

Collaborators

Detail Information

Publications31

  1. pmc Which drug or drug delivery system can change clinical practice for brain tumor therapy?
    Tali Siegal
    Gaffin Center for Neuro Oncology, Hadassah Hebrew University Medical Center, Ein Kerem, P O Box 12000, Jerusalem 91120, Israel
    Neuro Oncol 15:656-69. 2013
    ....
  2. doi request reprint CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?
    Tali Siegal
    Gaffin Center for Neuro Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Blood Rev 26:97-106. 2012
    ..Future directions for evaluation and treatment of CNS disease are outlined. This complex and intriguing topic should be ideally investigated by prospective trials...
  3. ncbi request reprint Toxicity of treatment for neoplastic meningitis
    Tali Siegal
    Neuro Oncology Center, Hadassah Hebrew University Hospital, Ein Kerem, PO Box 12000, Jerusalem 91120, Israel
    Curr Oncol Rep 5:41-9. 2003
    ..Careful assessment of the benefits and potential adverse reactions to a particular therapy regimen is mandated...
  4. ncbi request reprint Strategies for increasing drug delivery to the brain: focus on brain lymphoma
    Tali Siegal
    Neuro Oncology Center, Hadassah Hebrew University Hospital, Jerusalem, Israel
    Clin Pharmacokinet 41:171-86. 2002
    ..The main focus is on primary CNS lymphoma, as it is a chemosensitive brain tumour and its management routinely utilises specialised strategies to enhance drug delivery to the affected CNS compartments...
  5. ncbi request reprint In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans
    T Siegal
    Department of Nuclear Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel
    J Neurosurg 92:599-605. 2000
    ..The authors, therefore assessed the time course to barrier closure after osmotic BBB disruption in humans...
  6. ncbi request reprint Cellular and secretory mechanisms related to delayed radiation-induced microvessel dysfunction in the spinal cord of rats
    T Siegal
    Department of Neurology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    Int J Radiat Oncol Biol Phys 36:649-59. 1996
    ....
  7. ncbi request reprint Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma
    E Zylber-Katz
    Division of Medicine, the Neuro Oncology Center, Hadassah University Hospital, Jerusalem, Israel
    Clin Pharmacol Ther 67:631-41. 2000
    ....
  8. doi request reprint Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience
    S Frenkel
    Department of Ophthalmology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Br J Ophthalmol 92:383-8. 2008
    ..To describe our experience in treating vitreoretinal involvement of primary central nervous system lymphoma, by intravitreal injections of methotrexate (MTX)...
  9. doi request reprint Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption
    J Vicuna-Kojchen
    Department of Ophthalmology, Hadassah Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel
    Br J Ophthalmol 92:231-5. 2008
    ..To determine the incidence and characteristics of maculopathy associated with blood-brain barrier disruption (BBBD) which is used in treating primary central nervous system lymphoma (PCNSL)...
  10. pmc Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades
    Iris Lavon
    Gaffin Center for Neuro Oncology and the Department of Neurology, Hadassah Hebrew University Medical Center, Ein Kerem, PO Box 12000, Jerusalem 91120, Israel
    Neuro Oncol 12:173-80. 2010
    ..The sensitivity is moderate and specificity is high for both low- and high-grade tumors. Future studies should identify a panel of biomarkers that bear the highest potential for clinical application...
  11. pmc Gliomas display a microRNA expression profile reminiscent of neural precursor cells
    Iris Lavon
    Department of Neurology, Hadassah Hebrew University Medical Centre, Leslie and Michael Gaffin Centre for Neuro Oncology, Jerusalem, Israel
    Neuro Oncol 12:422-33. 2010
    ..Furthermore, careful study of the 15 miRNAs that differ in expression between SCs and gliomas, particularly those 5 that are not SC-specific, may enhance our understanding of gliomagenesis...
  12. ncbi request reprint Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase
    Iris Lavon
    Leslie and Michael Gaffin Center for Neuro Oncology, Department of Neurology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Cancer Res 67:8952-9. 2007
    ..The findings of our study strongly suggest that NF-kappaB plays a major role in MGMT regulation and that MGMT is most probably the major player in NF-kappaB-mediated chemoresistance to alkylating agents...
  13. ncbi request reprint Late-delayed cerebral involvement in systemic non-Hodgkin lymphoma: a second primary tumor or a tardy recurrence?
    Alexander Lossos
    Leslie and Michael Gaffin Center for Neuro Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    Cancer 101:1843-9. 2004
    ..The authors attempted to investigate the clonal relation between the late-delayed central nervous system involvement and the original systemic tumor...
  14. pmc Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model--an MRI study
    Rinat Abramovitch
    The Goldyne Savad Institute of Gene Therapy, MRI MRS Laboratory, HBRC, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Neoplasia 6:480-9. 2004
    ..This phenomenon was relatively moderate when compared to previous reports of other antiangiogenic agents used to treat brain tumors. We therefore conclude that HF is effective for treatment of metastatic brain tumors...
  15. ncbi request reprint Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas
    Iris Lavon
    Leslie and Michael Gaffin Center for Neuro Oncology, Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    Clin Cancer Res 13:1429-37. 2007
    ..Because little is known about the evolution of genetic and epigenetic changes that occur during tumor progression in oligodendrogliomas, we evaluated these changes in paired early and progressive oligodendrogliomas...
  16. ncbi request reprint Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial
    A Taliansky-Aronov
    Leslie and Michael Gaffin Center for Neuro Oncology, Hadassah Hebrew University Hospital, Ein Kerem, Jerusalem, Israel
    J Neurooncol 79:153-7. 2006
    ..The response of newly diagnosed AO to initial treatment with temozolomide (TMZ) has not yet been reported. This study evaluated the response and time to tumor progression of newly diagnosed AO initially treated with TMZ...
  17. ncbi request reprint Comparison of soluble dexamethasone sodium phosphate with free dexamethasone and indomethacin in treatment of experimental neoplastic spinal cord compression
    T Siegal
    Department of Neurology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    Spine (Phila Pa 1976) 13:1171-6. 1988
    ..005). The three agents differed in their ability to control the increases in water content and in PGE2 production, but proved almost equally effective in the prompt control of the specific gravity changes.(ABSTRACT TRUNCATED AT 250 WORDS)..
  18. ncbi request reprint Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression
    Netta Levin
    Leslie and Michael Gaffin Center for Neuro Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel imbar
    Cancer 106:1759-65. 2006
    ..However, to the authors' knowledge, limited data are available regarding the 1p/19q profile and its correlation with MGMT protein expression and response to treatment with DNA-alkylating drugs...
  19. ncbi request reprint Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme
    Arnold I Freeman
    Goldyne Savad Institute of Gene Therapy, Hadassah University Hospital, Jerusalem 91120, Israel
    Mol Ther 13:221-8. 2006
    ..One patient achieved a complete response. Intravenous NDV-HUJ is well tolerated. The findings of good tolerability and encouraging responses warrant the continued evaluation of NDV-HUJ in GBM, as well as other cancers...
  20. ncbi request reprint Central nervous system involvement in indolent lymphomas
    G Spectre
    Department of Hematology, Hadassah Hebrew University Hospital, Jerusalem, Israel 12000
    Ann Oncol 16:450-4. 2005
    ..Large series have reported this complication in 3% of indolent NHLs, generally following histological transformation...
  21. ncbi request reprint High incidence of thromboembolism in patients with central nervous system lymphoma
    Neta Goldschmidt
    Department of Hematology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    Cancer 98:1239-42. 2003
    ..The objective of this study was to evaluate the frequency and risk factors of VTE in patients with CNS lymphoma...
  22. ncbi request reprint Does streaming affect the cerebral distribution of infraophthalmic intracarotid chemotherapy?
    Ronit Agid
    Department of Radiology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    AJNR Am J Neuroradiol 23:1732-5. 2002
    ..We assessed whether streaming occurs with infraophthalmic, high cervical internal carotid artery (ICA) delivery of chemotherapeutic agents by means of conventional angiographic catheters...
  23. doi request reprint Primary T-cell CNS lymphoma presenting with leptomeningeal spread and neurolymphomatosis
    Netta Levin
    Leslie and Michael Gaffin Center for Neuro Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    J Neurooncol 90:77-83. 2008
    ..Diagnosis is difficult and, as a result, frequently delayed. This calls for early consideration of meningeal or nerve biopsy whenever CSF findings are inconclusive...
  24. ncbi request reprint CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course
    Dana Ekstein
    Department of Neurology, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel
    J Neurol Sci 247:39-46. 2006
    ..To assess whether clonal IgH genes in CSF of patients with CNS lymphoma correlates with the disease course...
  25. ncbi request reprint Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide
    Netta Levin
    Leslie and Michael Gaffin Center for Neuro Oncology and the Neuro Imaging Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel
    Neurology 63:354-6. 2004
    ..These results indicate that radiotherapy to extensive brain regions can be deferred until progressive disease is observed...
  26. pmc Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report
    Sigal Grisariu
    Gaffin Center for Neuro Oncology and Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Blood 115:5005-11. 2010
    ..An aggressive multimodality therapy can prevent neurologic deterioration and is associated with a prolonged survival in a subset of patients...
  27. ncbi request reprint Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy
    Felix Bokstein
    Neuro Oncology Center Hadassah Hebrew University Hospital, Jerusalem, Israel
    Leuk Lymphoma 43:587-93. 2002
    ..Durable responses are rare. Since both CNS and systemic relapses appear in tandem, future trials should evaluate alternative modalities in order to enhance drug delivery into the CNS...
  28. ncbi request reprint Chemotherapy delivery issues in central nervous system malignancy: a reality check
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Science University, Portland, and the Veterans Administration Medical Center, OR 97239 3098, USA
    J Clin Oncol 25:2295-305. 2007
    ..This review assesses the current state of knowledge regarding preclinical and clinical pharmacology for brain tumor chemotherapy and evaluates relevant brain tumor pharmacology studies before October 2006...
  29. ncbi request reprint Current status and future of relapsed primary central nervous system lymphoma (PCNSL)
    Rose Marie Tyson
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Leuk Lymphoma 44:627-33. 2003
    ....
  30. ncbi request reprint Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement
    Justine R Smith
    Casey Eye Institute, Oregon Health and Science University, Portland, Oregon 97201 4197, USA
    Ophthalmology 109:1709-16. 2002
    ..To evaluate the safety and efficacy of intravitreal methotrexate in the management of primary central nervous system lymphoma (PCNSL) involving the eye...
  31. ncbi request reprint The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R
    David J Gross
    Endocrinology and Metabolism Service, Department of Medicine, Hadassah University Hospital, P O B 12000, Jerusalem, Israel 91120
    Endocr Relat Cancer 13:535-40. 2006
    ..5 months), and disease progression in 1 patient; NET--disease progression in 1 patient. IM does not appear to be useful for treatment of malignant endocrine tumors, also causing significant toxicity in this patient population...